Impact of Non-glucose Signals on Glycemic Control in Patients With Type 1 Diabetes

Completed · Not applicable

Conditions studied: Type 1 Diabetes Mellitus

In brief

This clinical trial will identify exercise-related and emotional stress related effects on glycemic control in patients with type 1 diabetes using sensor-augmented pump (SAP) therapy.

Key facts

Study ID

NCT03307850

Run by

Sansum Diabetes Research Institute

People needed

20

Starts

2017-11-01

Expected to finish

2018-08-31

Last updated by the study team

2018-09-05

Who can join

Age: 18 and older, up to 75. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Age 18-75 years
• Clinical diagnosis, based on investigator assessment, of T1D for at least one year and using insulin for at least 1 year.
• Using an insulin pump for diabetes therapy for at least 3 months
• Demonstration of proper mental status and cognition for the study
• Non-smoker
• If not currently using CGM, willing to use CGM during the study
• An understanding of and willingness to follow the protocol and sign the informed consent

You may not qualify if…

• Admission for diabetic ketoacidosis in the 6 months prior to enrollment unless study team feels the subject is appropriate for study given complete clinical context for subject
• Severe hypoglycemia resulting in seizure or loss of consciousness > once in the 6 months prior to enrollment
• History of a seizure disorder (except hypoglycemic seizure), unless written clearance is received from a neurologist and not currently on a seizure medication
• Cystic fibrosis
• Unstable coronary artery disease or heart failure, unless written clearance is received from a cardiologist or primary care provider
• A known medical condition that in the judgment of the investigator might interfere with the completion of the protocol such as the following examples:
• Inpatient psychiatric treatment in the past 6 months
• Presence of a known adrenal disorder or chronic oral steroid therapy
• Abnormal liver function test results (Transaminase >3 times the upper limit of normal); testing required for subjects taking medications known to affect liver function or with diseases known to affect liver function
• Abnormal renal function test results (calculated GFR <60 mL/min/1.73m2);
• Active gastroparesis (defined actively being treated with medications)
• If on antihypertensive, thyroid, anti-depressant or lipid lowering medication, lack of stability on the medication for the past 2 months prior to enrollment in the study
• Abuse of alcohol or recreational drugs
• Pregnancy
• Infectious process not anticipated to resolve prior to study procedures (e.g. meningitis, pneumonia, osteomyelitis).
• Uncontrolled arterial hypertension (Resting diastolic blood pressure >90 mmHg and/or systolic blood pressure >160 mmHg) at the time of screening
• Uncontrolled microvascular complications such as current active proliferative diabetic retinopathy defined as proliferative retinopathy requiring treatment (e.g. laser therapy) in the past 12 months.
• A recent injury to body or limb, muscular disorder, use of any medication, any carcinogenic disease, or other significant medical disorder if that injury, medication or disease in the judgment of the investigator will affect the completion of the protocol.

Where it is running

• Sansum Diabetes Research Institute — Santa Barbara, California, United States
• Mayo Clinic — Rochester, Minnesota, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.